Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 0.43 |
| ▸ | USP2 | O75604 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.39 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.39 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | XBP1 | P17861 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL879426 | 0.91 | L3MBTL1 (0.43) | L3MBTL1USP2MAPTMEN1KMT2A | |
| Sipagladenant SCHEMBL879438 | 0.88 | L3MBTL1 (0.47) | L3MBTL1USP2MAPTMEN1KMT2A | |
| SCHEMBL10331934 | 0.87 | L3MBTL1 (0.46) | L3MBTL1USP2MAPTMEN1KMT2A | |
| SCHEMBL846371 | 0.86 | L3MBTL1 (0.44) | L3MBTL1USP2MAPTMEN1KMT2A | |
| SCHEMBL1257097 | 0.86 | L3MBTL1 (0.46) | L3MBTL1USP2MAPTMEN1KMT2A | |
| SCHEMBL879437 | 0.86 | L3MBTL1 (0.46) | L3MBTL1USP2MAPTMEN1KMT2A | |
| SCHEMBL846136 | 0.86 | TDP1 (0.44) | L3MBTL1USP2MAPTMEN1KMT2A | |
| SCHEMBL846999 | 0.84 | L3MBTL1 (0.43) | L3MBTL1USP2MAPTMEN1KMT2A | |
| SCHEMBL1255617 | 0.84 | L3MBTL1 (0.51) | L3MBTL1USP2MAPTMEN1KMT2A | |
| SCHEMBL1255445 | 0.84 | L3MBTL1 (0.46) | L3MBTL1USP2MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200247798-A1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | KYOWA KIRIN CO LTD (JP) | 2020-08-06 | — | — | US | disclosed |
| US-10407440-B2 | Therapeutic agent for motor disorders | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-09-10 | — | — | US | disclosed |
| EP-3378860-A1 | THERAPEUTIC AGENT FOR MOTOR DISORDERS | Kyowa Hakko Kirin Co., Ltd. (JP) | 2018-09-26 | — | — | EP | disclosed |
| EP-2433938-B1 | THERAPEUTIC AGENT FOR MOTOR DISORDERS | KYOWA HAKKO KIRIN CO LTD (JP) | 2018-04-18 | — | — | EP | disclosed |
| US-20170275296-A1 | THERAPEUTIC AGENT FOR MOTOR DISORDERS | KYOWA KIRIN CO., LTD. (JP) | 2017-09-28 | — | — | US | disclosed |
| US-9714257-B2 | Therapeutic agent for motor disorders | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-07-25 | — | — | US | disclosed |
| EP-2474544-B1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | KYOWA HAKKO KIRIN CO LTD (JP) | 2017-07-12 | — | — | EP | disclosed |
| EP-2474543-B1 | THERAPEUTIC AGENT FOR MOOD DISORDERS | KYOWA HAKKO KIRIN CO LTD (JP) | 2017-05-03 | — | — | EP | disclosed |
| US-9249135-B2 | Therapeutic agent for mood disorders | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2016-02-02 | — | — | US | disclosed |
| US-20150225417-A1 | THERAPEUTIC AGENT FOR MOTOR DISORDERS | KYOWA KIRIN CO., LTD. (JP) | 2015-08-13 | — | — | US | disclosed |
| CN-102414209-B | Therapeutic agent for dyskinesia | KYOWA HAKKO KIRIN CO LTD | 2015-01-28 | — | — | CN | disclosed |
| US-20120184554-A1 | THERAPEUTIC AGENT FOR MOOD DISORDERS | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-07-19 | — | — | US | disclosed |
| EP-2474543-A1 | THERAPEUTIC AGENT FOR MOOD DISORDERS | Kyowa Hakko Kirin Co., Ltd. (JP) | 2012-07-11 | — | — | EP | disclosed |
| EP-2474544-A1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | Kyowa Hakko Kirin Co., Ltd. (JP) | 2012-07-11 | — | — | EP | disclosed |
| US-20120172362-A1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-07-05 | — | — | US | disclosed |
| CN-102482271-A | Therapeutic agent for anxiety disorder | KYOWA HAKKO KIRIN CO LTD | 2012-05-30 | — | — | CN | disclosed |
| CN-102482272-A | Therapeutic agent for mood disorders | KYOWA HAKKO KIRIN CO LTD | 2012-05-30 | — | — | CN | disclosed |
| US-20120101101-A1 | THERAPEUTIC AGENT FOR MOTOR DISORDERS | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-04-26 | — | — | US | disclosed |
| CN-102414209-A | Therapeutic agent for dyskinesia | KYOWA HAKKO KIRIN CO LTD | 2012-04-11 | — | — | CN | disclosed |
| EP-2433938-A1 | THERAPEUTIC AGENT FOR MOTOR DISORDERS | Kyowa Hakko Kirin Co., Ltd. (JP) | 2012-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184554-A1 | THERAPEUTIC AGENT FOR MOOD DISORDERS | TPH1, HDAC1, HDAC2 | L3MBTL1 2006/4885USP2 4242/4885MAPT 230/4885 |
| US-10407440-B2 | Therapeutic agent for motor disorders | DDT, COMT, SLC6A3 | L3MBTL1 699/4885USP2 3774/4885MAPT 241/4885 |
| US-20170275296-A1 | THERAPEUTIC AGENT FOR MOTOR DISORDERS | DDT, COMT, SLC6A3 | L3MBTL1 699/4885USP2 3774/4885MAPT 241/4885 |
| US-20120172362-A1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | TAAR1, SLC6A1, GABBR1 | L3MBTL1 1461/4885USP2 3596/4885MAPT 766/4885 |
| US-20120101101-A1 | THERAPEUTIC AGENT FOR MOTOR DISORDERS | DDT, COMT, SLC6A3 | L3MBTL1 699/4885USP2 3774/4885MAPT 241/4885 |
| US-20200247798-A1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | TAAR1, SLC6A1, GABBR1 | L3MBTL1 1461/4885USP2 3596/4885MAPT 766/4885 |
| US-20150225417-A1 | THERAPEUTIC AGENT FOR MOTOR DISORDERS | DDT, COMT, SLC6A3 | L3MBTL1 699/4885USP2 3774/4885MAPT 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.